Info

🌱 來自：mantle cell lymphoma

Initial Treatment: Transplant Eligible Patients of mantle cell lymphoma

• No generally accepted standard of care; clinical trial enrollment encouraged
• In pts who require Rx & can tolerate it, an upfront autologous transplant approach is favored by most groups (Blood 2005;105:2677)
• Pts typically receive alternating or sequential schedules of multiagent chemotherapy. Rituximab is included in all cycles of chemotherapy. Inclusion of high-dose cytarabine (alone or in combination) as part of chemotherapy has been shown to improve outcomes.
• Alternating schedules include (eg, R-Hyper-CVAD (JCO 2005;23:7013) & Nordic MCL-2 (R-Maxi-CHOP alt. R-HiDAC, Blood 2008 112:2687)
• Sequential schedules include R-CHOP ã R-DHAP (Blood 2013;112:48) or R-CHOP ã R-ICE (Ann Oncol 2010;21:133)
• Rituximab maintenance improves PFS & OS after R-DHAP → HDT/ASCR (LyMa trial, ASH 2016, #145)

---

• Design: Phase II clinical trial, multi-center, randomized, open-label
• Number of patients: 85
• Patients characteristics: Newly diagnosed mantle cell lymphoma (MCL) patients
• Agent: Obinutuzumab in combination with chemotherapy and in maintenance after ASCT, Rituximab used as a comparator
• Treatment line: Frontline therapy in MCL patients
• Trial Acronym: LYMA-101 (NCT02896582)
• Compare efficacy: | Outcome | Obinutuzumab Group | Rituximab Group | | ------- | ------------------ | --------------- | | PFS | 82.8% | 66.6% | | OS | 86.4% | 71.4% |
• One line summarize: Obinutuzumab provides better disease control and enhances progression-free survival (PFS) and overall survival (OS) compared to Rituximab in transplant-eligible mantle cell lymphoma patients.